Macitentan

马昔腾坦

Report date: 2026/04/05 20:00:15
NME

Base Information

Drug NameMacitentan
Drug Alias Namemacitentanum玛西腾坦马西替坦ZependoOpsumit +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEndothelin receptor type A antagonistsEndothelin receptor type B antagonists
TargetsEndothelin receptor type AEndothelin receptor type B
Therapy Area/IndicationsChronic thromboembolic pulmonary hypertensionScleroderma-associated interstitial lung diseasesUlcer +[17] 
Global Approved IndicationsPulmonary Arterial Hypertension
Approved Indications in ChinaPulmonary Arterial Hypertension
Original Approved Country/TerritoryUnited States
Original Approved Date2013/10/18
Country/TerritoryCzechiaBelgiumBulgaria +[54] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesActelion Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesActelion Pharmaceuticals Us IncJohnson & Johnson Innovative MedicineJohnson & Johnson (China) Investment Ltd +[11] 
Inactive CompaniesUniversity Of PittsburghJanssen Pharmaceutical KkUniversity Of Maryland, Baltimore +[5] 
Active IndicationsChronic thromboembolic pulmonary hypertensionChronic DiseaseThromboembolism +[7] 
Inactive IndicationsScleroderma-associated interstitial lung diseasesUlcerScleroderma, Systemic +[10] 

Other Information

ATC CodeC02KX04
Related LinksWikipediaDrugBankKEGG